International Journal of
INTELLIGENT SYSTEMS AND APPLICATIONS IN ENGINEERING
ISSN:2147-6799 www.ijisae.org Original Research Paper

The Role of Artificial Intelligence in Revolutionizing Drug Discovery and Advanced Pharmaceutical Manufacturing

Saja Hikmat Dawood[1], Mohammed Nsaif Mustafa Al_Ani [2]

Submitted:10/03/2024 **Revised**: 25/04/2024 **Accepted**: 02/05/2024

Abstract: The COVID-19 pandemic has brought into focus the urgent requirement for revolutionary drug discovery and pharmaceutical manufacturing processes. AI has reinvented the expensive and cumbersome way of drug discovery by boosting it with advanced computational hardware. Recent applications of AI span multiple stages in the drug discovery pipeline, from de novo design to drug response profiling. The article provides a review of AI methodologies here, data quality issues and ethical challenges associated with them, as well as strategies to combat these issues.

The FDA's Pharmaceutical Quality for the 21 st Century Initiative is also responsible for developing advanced manufacturing technologies that promise to further increase drug quality and supply chain resilience. The use of AI for optimizing manufacturing processes, and more specifically, their modular and distributed approaches is also explored.

The review ends by taking a closer look at development in AI-based biotech startups, giving an overview of how AI has affected drug discovery and pharmaceutical manufacture.

Keywords: *Artificial Intelligence (AI), Drug Discovery, Advanced Pharmaceutical Manufacturing*

1. Introduction

The COVID-19 crisis has brought home the need for thinking outside the box - or bloodstream, in this case. DESIGN-Of-CHEMICAL INTRODUCTION The conventional process of drug discovery, which is quite expensive, complicated and has a high failure rate, has changed tremendously with the advent of Artificial Intelligence (AI). Advances in computational hardware such as cloud computing, GPUs and TPUs has dramatically improved the ability of AI. Most recently, AI tools are being applied throughout the drug discovery pipeline ranging from de novo drug design to property prediction and analysis of drug responses.

Revision: Medicinal Chemistry in the Era of AI -A Critical Review on the Transformative Nature of Artificial Intelligence Using AI applied to medicinal chemistry has been under a spotlight that is still gaining intensity and can have real evolving power in drug discovery field. Historically, drug discovery has been driven mostly by manual methods (lots of trial-and-error experimentation and high-throughput screening), but new machine learning (ML) and natural language processing (NLP)-based AI technologies are enabling efficiencies in the field.. These upgrades permit the quick analysis of numerous data, thereby enhancing the overall efficiency and effectiveness in drug discovery workflows. First, AI could be used to predict the efficacy and toxicity of new agents and thereby streamline their development into clinical trials.

The FDA's Pharmaceutical Quality for the 21st Century Initiative similarly promotes emerging manufacturing technologies to assure drug quality and availability. These technologies, backed by the FDA Emerging Technology Program, have the potential to improve the buffering and resilience of pharmaceutical manufacturing - especially against ever-evolving market needs. The recent advent of advanced manufacturing has introduced new technological possibilities (or novel applications of established techniques) that may be applicable for new drug products and existing drug products to enhance the reliability and robustness of the manufacturing process.

This review discusses how advancing AI technologies such as graph neural networks, reinforcement learning, or molecular simulations are leveraged for drug discovery. It covers issues of data quality, ethics and the limitations of AI methods and gives strategies such as data augmentation or explainable AI to address those. In addition, it explores how AI can help to optimize manufacturing methodologies such as modular and distributed manufacturing for precision medicine and point-of-care solutions.

It concludes with a survey of emerging AI-based biotech startups and how recent financial investment round highlight both the depth of progress so far and the promise for new developments in the space. The purpose of this review is to summarize the transformative potential of AI in drug discovery, and advanced pharmaceutical processing spanning an overall view of current limitations and future prospects.

[1]Computer Science Department, College Of Basic Education, Mustansiriya University, 14022, Baghdad, Iraq
[2]Computer Engineering Department, College Of Basic Education, Mustansiriya University, 14022, Baghdad, Iraq



Fig 1. :- Machine Learning Collaboration

1-1 Introduction to AI in Drug Discovery and Advanced Pharmaceutical Manufacturing

Key Points:

1. The requirement of an innovative approach in drug discovery and better pharmaceutical manufacturing accessible to the Clinic is reenforced by the pandemic COVID-19.

2. Traditional hurdles in the drug-discovery landscape: Drug discovery has always been expensive, intricate and carries a high failure rate with it.

3. Role of AI:

Improved Capabilities: AI applications have benefited from advances in computational hardware (the cloud, GPUs, TPUs)

- Pipeline Stages: AI is adopted into different stages from de novo drug design, property prediction and to drug response analysis.

Efficiency and Accuracy: Data analysis efficiency and accuracy are improved through AI technologies like machine learning and natural language processing.

Predicting Efficacy and Toxicity AI helps to predict drug efficacy and toxicity, speeding up new drug discovery.

4. Pharmaceutical Quality Initiative within the FDA:

Support for Advanced Manufacturing: For drug quality and supply chain resilience-enhancing technologies

Emerging Technology Program: Helps to integrate advanced manufacturing techniques.

Manufacturing Process Optimization: AI will also enable modular and distributed manufacturing approaches to precision medicine and point-of-care solutions.

5. Challenges and Strategies:

Data Quality and Ethics Using AI to Encourage Ethical Behavior

Mitigation Strategies: Data augmentation and explainable AI to tackle these challenges.

6. AI-Based Biotech Startups:

Progress and Potential: A look into the recent development and potential impact of AI-driven start-ups in biotech



Fig 2 :- Here's A Representation Of The Key Points In The Overview

1-2 Research Background:-

According to the ESFRI White Papers, the main issue recognized is that innovative and cost-effective methods are required to address guidelines in drug discovery and pharmaceutical manufacturing that have been magnified during the COVID-19 pandemic. The following are the bullet points giving an overview of what the problem is:

Main Problem:

1. Traditional Drug Discovery Process Problems

Traditional drug discovery is costly.

Work was carried out with Figure 11; however more is required as creating the appropriate shapes takes with it a lot of effort.

Failure Can Be A Norm: Many drugs simply do not work

2. Need for Innovation:

The second is that it is apparent as never before that the COVID-19 pandemic has underlined the urgent need for an even sharper removal of bottlenecks from drug discovery to manufacture.

3. Role of AI

4. FDA's Perspective of Pharmaceutical Quality by Design (QbD)

5. Challenges

6. AI-Based Biotech Startups



Fig 3. :- Mentions The Key Elements Of Data, Decision Making, And Disruption

Here's a detailed diagram visualizing the main points and the proposed solution for improving drug discovery and pharmaceutical manufacturing. The diagram outlines the following components:

2- State-of-the-Art Solutions from Prior Work

1. Utilizing AI Technologies:

From research to practice: Graph neural networks for predicting properties of molecules and materials

Reinforcement Learning: The use of reinforcement learning as a novel optimizer for drug compounds, where the molecular structures are iteratively improved to align with selected desired properties.

Molecular Simulations: A way to obtain the nitty grittiest details about molecule interactions Elderberry Removal, in addition that can supply you detailed information regarding how a particular technique fares in terms of drug response hence it is turning out to be among the strong predictors for efficacy and also toxicities.

2. Introduction Executive Summary Why Viega Adopted A No-Load Facility How Advanced Manufacturing Technologies Are Redefining Processes Faster "flexibility" due to integrated controls Design Reduced Time By 50% Production Risk Assessment Continuous improvement Anwita Basu Jim Chew Dale Roberts Steve Hester Erik Holladay Don Foster 1.

FDA Pharmaceutical Quality for the 21st Century Initiative: Supporting the adoption of new manufacturing technologies and assuring product quality and supply chain integrity.

Modular, Distributed Manufacturing: AI processes will increase manufacturing robustness and flexibility to advance the production of precision medicine and point-of-care solutions.

Emerging Technology Program -Grant competition that funds the development and implementation of innovative or underutilized manufacturing processes to respond to market trends.

3. In the words of Johan Zietsman: tackling the data and moral problems

Random Cropping and other data augmentation techniques- re-shape images during training to help the model perform better.

Explainable AI - methods that allow AI decisions to be understood, thus serving ethical requirements and providing confidence when using app AI.

Quality and Ethics: In this we will also learn how to create a high-quality data and we will learn how to apply ethics principles to the research in ai and its applications.

4. AI-Based Biotech Startups:

Understanding the progress and promise behind AI-driven bio-tech startups and investments that have most taken stride towards changing Drug discovery inernet, maybe more widely in next generation manufacturing.

Take from Earlier Works:

1. Impact of COVID-19:

This further highlighted how drugs were radically searched for and synthesized differently than earlier approaches,

2. Challenges in traditional Drug Discovery

Increase prices, complexity and failure-rates inflamed discussions on alternative approaches.

3. Role of AI:

Advantages: It reinforces the analytical capabilities of (already strong) departments, streamlines data analysis and enhances predictions regarding drug efficacy and safety profiles with fast turnaround times for introducing new drugs.

4. Pharmaceutical Quality Initiative of the FDA

- Advances manufacturing technologies to modernize drug quality and the resiliency of supply chains;

5. Challenges and Strategies:

Data quality andethical issues need to be dealt with, such as through data augmentation, explainable AI etc.

6. AI-Based Biotech Startups:

At that time some of what was said about the development and advances in AI driven startups and there impact on the biotech industry.



Fig 4. :- Here's A Detailed Diagram Visualizing The Utilization Of Ai Technologies In Drug Discovery. The Diagram Highlights Three Key Ai Methodologies

3- Problem Statement:

Drug discovery and pharmaceutical manufacturing have traditionally been (and still are) lengthy, expensive processes that involve a lot of steps, are incredibly complicated, and have high failure rates. The COVID-19 pandemic has only amplified this shortfall with huge leadtime and inefficiencies in many of these domains, necessitating innovation that is both quicker and more efficient. We have an urgent need to improve the drug discovery pipeline, make manufacturing efficiency more efficient and be assured of drug quality and supply chain stability. Whilst the adoption of AI and advanced manufacturing techniques promises a solution, it does introduce complications with respect to data quality (both reliability and relevance), ethical implications, and deployment.

Key Highlights of Problem Statement:

Traditional Drug Discovery Hurdles

- High costs

- Complexity

- High failure rates

Below These processes are shown schematically:-



Fig 5. :- Data Flow Through A Deep Neural Network

4- Research Questions

Traditional drug discovery and pharmaceutical manufacturing, also had four key challenges.

1- Which AI approaches are being incorporated for drug discovery?
2- How to address data quality and ethical concerns?
3- So, why do we even require innovative processes in drug discovery and pharmaceutical manufacturing?
4- How has the crisis of COVID-19 underlined that drug discovery and production needs to be a lot more efficient?
5- More power for drug discovery with AI?
6- How has the next generation of computing hardware (cloud, pre-insternal TPUs, GPUs) enabled ai applications for drug discovery?
7- Artificial intelligence methods in drug discovery, how have these emerged through tools like graph neural networks, reinforcement learning and molecular simulations?

5- Research Objectives

Q1:- What are the prime difficulties in traditional drug discovery and pharmaceutical manufacturing?

Aim :- To understand the main challenges in traditional drug discovery and pharmaceutical manufacturing including high cost, complexity and low success rate.

1:- Which are the AI approaches being utilized in drug discovery?

Purpose:- This paper examines the different AI methods like graph neural networks, reinforcement learning, molecular simulations applied in the drug discovery cycle and how significant those methods are providing more insights.

Q3 what are some queality measures recommended to strength care data quality and ethics in AI today (drug discovery)?

Summary Objective: In this review we consider some of the proposed strategies to underpin data integrity and ethical considerations in AI based drug discovery (including e. g. data augmentation and explainable AI), here-after identifying how they may help shape a robust framework allowing wider implementation of AI across pharma landscape.

6- Research Scope

The present review endeavours to exhaustively investigate and assess the substantial contribution of Artificial Intelligence (AI) in changing both drug discovery procedure and pharma manufacturing process focusing upon following areas:

1. Problems with Conventional Drug Discovery and Manufacturing:

- High Costs: Research on the Cost of Traditional Drug Discovery

- Complexity: Look at the complex and laborious methods drug development has employed historically

High Failure Rates:Examine how and why failings in typical drug discovery are happening so frequently.

2. Similarly, integration of AI methodologies has also gained a lot of traction in drug discovery.

Graph Neural Networks: See if the networks can summarize actual molecular structures and predict property

Reinforcement Learning - Exploring how reinforcement learning can be applied in creating better drug compounds and molecular structures.

Molecular Modeling: Look at how molecular modeling has been used to go beyond general insight into the workings of molecules and delve deep into specific molecular interactions that are key to the interpretation of drug response and prediction of efficacy/toxicity.

3. Ways to data quality and ethical issues relations:

DATA Augmentation: Strategies for making the size of datasets bigger in order to give more signals to AI model training and improve quality.

- Explainable AI: A way to evaluate whether some AI decisions are transparent and interpretable with decisional audit, and how they may help to mitigate huge ethical risks and build better trust over the AI.

Quality: making sure that we have good data, and Ethics: ensuring that everyone continues to maintain high standards of ethical behavior in our AI work.

4. This list of breakthroughs is designed to give you a sense of what we have accomplished in computational hardware thus far, but why would more powerful hardware specifically be useful for AI applications?

Progress in computational hardware (e.g., cloud computing, GPUs, TPUs and their application to AI in drug discovery for more efficient processing and analysis of large experimental datasets)

5. The Pharmaceutical Quality for the 21st Century Initiative of FDA:

Advanced manufacturing technologies: Assess the FDA's efforts to incorporate advanced manufacturing technologies that enhance drug quality and supply chain resilience.

Modular & distributed manufacturing: Investigate how AI can improve these modes of manufacturing to enable the precision medicine and point-of-care solutions.

6. Covid-19 Pandemic Impacts:

- Innovation Pressure: Consider how the COVID-19 pandemic placed a premium on faster, cheaper ways to discover and manufacture new drugs

7. AI-powered biotech gains and growing pains

Developments and Investments - Pan out the AI-driven biotech startups that have laid their focus on groundbreaking developments and this will enable you to step into the come-of-age promises and possibilities of transforming biotech industry

production of a candidate drug is shown below this process is shown below:



Fig 6. :-Production Of A Candidate Drug Is Shown(This Process)

7- Research Significance:

The importance of this study is the complete coverage of the topic that explores how Artificial Intelligence (AI) can potentially change the drug discovery and pharmaceutical production field [4]. This is especially important in a low-margin environment and for industries with long-standing challenges of high costs, complexity, and high failure rates:

1. Meeting Immediate COVID-19 Related Needs:

The COVID-19 pandemic has further lent urgency to the need for fast and novel methods of drug discovery and production. This work is important in its exploration of how AI can speed up these processes, serving to address an urgent global health problem.

2. Enhance efficiency and reduce costs:

However, traditional drug discovery is costly and time consuming. AI methods like graph neural network and reinforcement learning can automatize them, which would save significant resources.

3. Improving the Accuracy and Minimizing Failures:

The study is intended to show how AI can enhance the precision of drug discovery, reducing traditional high

failure rates. This speeds up the delivery of successful and safe medications.

4. Reducing Data Quality and Ethical Issues

Concerns about data quality and ethics that enter into the picture when AI is used for drug discovery This investigation focused on the mitigation of such strategies is data augmentation and explainable AI to maintain the transparency and ethicality of various decisions through the overall process, building trust with all AI driven processes.

5. Using Hi-Tech Computational Hardware:

The right hardware support like cloud, GPUs and TPUs are very essential for successful AI application run. This paper explore how thoses technologies are applied to how process and analyzed large datasets, contributing the efficiency of AI.

6. Helping FDA in their Initiatives for Pharmaceutical Quality:

The study is consistent with the aims of FDA's Pharmaceutical Quality for The 21st Century Initiative, which supports innovative manufacturing techniques. The research, by demonstrating AI's potential to enhance manufacturing performance, thus informs ongoing efforts to promote drug quality and supply chain security.

7. Fostering Innovation Through Biotech Startups

One of the most promising impacts of artificial intelligence on the pharmaceutical trade is by AI-driven biotech startups. The report is all about progress and the way in which these startups can drive the drug discovery and manufacturing.

8. With A Full Picture,

This research surveys and reviews multiple AI methodologies from the perspective of all stages of drug discovery and development, thus delivering a comprehensive overview for pharmaceutical stakeholders.

Fig 7. :- Drug Development Process: Target Deconvolution Vs. Target Discovery.

8-Research Gap

Viewing of a piece gives one to think about so much, and it does an excellent job of describing the role AI can play in reshaping drug discovery and pharma manufacturing, but also gives something to explore in terms of a research gap and avenues for further study.

1. AI in Drug Discovery - The Fledgling Years

Here is an example where one could have given you a review paper about how AI can be used across phases in drug discovery pipeline and written zilch about inserting AI into e.g. target ID/ validation etc.

2. AI in Clinical Trials:

If AI promises to forecast what works best in drug development, why is there so little talk of how it can optimize the design and patient recruitment processes that run headlong into trial success - both critical parts of how we develop new drugs, and among the places where AI is strongest?

3. Real world application, few case studies:

There must be real life examples of Beta programs which has resulted in AI applications with drug discovery, and manufacturing. The other consequence is that there is a big hole of understanding in practical applications on real problems and potential solutions, how to apply AI in life sciences.

4. Regulatory challenges and standards

The review only touches upon the actions taken by the FDA and does not discuss addressing these new issues including regulatory challenges or guiding principles to develop necessary standards for safe deployment of AI based solutions for drug discovery and small molecule pharmaceutical manufacturing.

5. Scaling and Generalizability in AI Models:

The research about the scalability and generalizability of AI models for other drug classes and manufacturing processes that are key to industry adoption has not addressed.

6. Interdisciplinary Team)initWithFrame:

Further detail is needed on the AI specialist-biologist-chemist-regulator interdisciplinary collaboration necessary for optimal integration of AI into drug discovery and manufacturing.

7. Sustainability in the long run

Most of all, I am curious about what AI will mean for the pharmaceutical industry in terms of sustainability.(read as - whether it can scale) and how we are going to look at job displacement or new areas of work.

8. Ethical Frameworks and Transparencyethical-frameworks-and-transparency

- Ethical aspects are pointed out, but not in a proper structured manner with thorough guidelines and framework that lead to some transparency and ethical issues in AI applied to Pharma industry.

9. Patient-Centric Care with AI

The article does not go into much depth on the use of AI to provide precision medicine strategies for patient needs matching, what is a very hot topic in the pharma industry.

10. Side Effects and the Economic Impact => Cost Benefit Analysis

There is no evaluation of the economic consequences and cost-benefit ratio associated with AI applications in drug discovery and manufacturing that may help industrial stakeholders decide whether to invest in AI technologies.

Future work directed at addressing these research gaps will offer a better, more practically useful view on the approvable role AI can play in drug discovery and pharmaceutical manufacturing which will eventually translate to tangible progress within the field, and adoption across the industry.

Fig 8. :-Research Gaps In Ai Role In Drug Discovery And Pharmaceutical Manufacturing

Research gaps in AI role in drug discovery and pharmaceutical manufacturing indicated inside the diagram above . Gaps between the nodes are interconnected, and the presence of directed edges clearly illustrates how these node-level failures feed into each other create a global vulnerability.

9-Research Framework:-

Given the extensive literature coverage of AI in drug discovery and pharmaceutical manufacturing, along with identified research challenges this framework can break down to the following component-categories:

9-1 Methodology

Literature Review - By utilizing current literature on application of AI in drug discovery and pharmaceutical manufacturing.

Case Studies: Real application and successful use cases

Surveys and Interviews: Collecting wisdom from experts in a particular industry, AI specialists, biologists, chemists and regulatory bodies;

Data Analysis: Using AI methodologies such as graph neural networks, reinforcement learning, and molecular simulations to analyze data and predict drugs efficacy and toxicity.

Ethical Analysis: To establish an ethical frame-work and guidelines for the application of AI in Pharmaceuticals.

Economic Analysis: How should we think about cost-benefit in AI deployment in drug discovery and manufacture?

9-2 Expected Outcomes:-

In-depth knowledge of the hurdles facing conventional drug discovery and production

Identification of the successful methodologies that AI has brought about in drug discovery

Strategies that could be used to overcome data quality and ethical concerns were also discussed.

Insights on the importance of modern computer hardware for ai applications

FDA's moves and their influence on AI adoption assesment

So, as AI seeps into the biotech sector in order to rewrite the biology applications rulebook of life sciences deals, I will be featuring a league table of AI-based biotech startups, tracking their progress and potential.

Overview of Research gaps and Future Studies - The Most Crucial part of the Paper

This diagram provides a clear structure for the research framework, illustrating the interconnected components and the flow of the research process.



Fig 9. :- Artificial Intelligence Employs Machine Learning And Neural Network Techniques To Effect

10-Problem Formulation:

The primary problem this research aims to address is the inefficiency, high cost, complexity, and high failure rates in the traditional drug discovery and pharmaceutical

production processes. These challenges have been further exacerbated by the COVID-19 pandemic, which has highlighted the urgent need for faster and more innovative methods of drug development. The central focus of the research is to explore how Artificial Intelligence (AI) can revolutionize these processes to improve efficiency, reduce costs, and enhance the success rates of drug development.

Key Aspects of the Problem:

1. Traditional Drug Discovery Challenges

2. Impact of COVID-19

3. AI's Potential Contributions

4. Regulatory and Ethical Considerations

5. Scaling and Generalizability

6. Real-World Applications and Case Studies

7. Economic and Sustainability Concerns

11-Research Objectives:

- To explore AI methodologies and their potential to transform drug discovery and pharmaceutical production.

- To address and mitigate data quality and ethical issues in AI applications.

- To evaluate the impact of advanced computational technologies on AI performance in drug discovery.

- To examine the role of AI in supporting regulatory efforts and enhancing drug quality.

- To identify successful AI-driven biotech startups and their contributions to the pharmaceutical industry.

- To provide a comprehensive overview of the current state and future prospects of AI in drug discovery and pharmaceutical manufacturing.

12-Expected Outcomes:

- In-depth understanding of the challenges and inefficiencies in traditional drug discovery and production.

- Identification of AI methodologies that have successfully improved drug discovery processes.

- Strategies to address data quality and ethical concerns.

- Insights into the importance of modern computational hardware for AI applications.

- Assessment of FDA initiatives and their influence on AI adoption.

- Overview of emerging trends and progress in AI-based biotech startups.

This research aims to establish a strategic plan for integrating AI into the pharmaceutical lifecycle, addressing current challenges, and paving the way for future advancements in drug development and manufacturing.

Write to me The Proposed Solution from the above section and according to the information provided by me? Briefly

13-Proposed Solution

To address the inefficiencies, high costs, complexity, and high failure rates in traditional drug discovery and pharmaceutical production, the proposed solution involves integrating Artificial Intelligence (AI) technologies into these processes. The key components of this solution are:

1. AI Methodologies for Drug Discovery

2. Data Quality and Ethical Considerations

3. Advanced Computational Technologies

4. Regulatory Support and Compliance

5. Innovation through Biotech Startups

6. Comprehensive Review and Case Studies

7. Economic and Sustainability Analysis



Fig 10. :-Comprehensive Diagram Of The Problems In Traditional Drug Discovery And Production

The code will include placeholders for key components such as data processing, AI model training, and evaluation.

import numpy as np

import pandas as pd

from sklearn. from sklearn import model_selection from sklearn.model_selection import train_test_split

from sklearn. metrics import accuracy_score

from tensorflow. keras. models import Sequential

from tensorflow. keras. layers import Dense

import tensorflow as tf

Placeholder for loading and preprocessing data

def load_and_preprocess_data(file_path):

data = pd.read_csv(file_path)

Placeholder for data preprocessing steps (e.g., normalization, feature selection)

return data</p>

Placeholder for AI model creation (e.g., graph neural networks, reinforcement learning models)

def create_ai_model(input_shape):

model = Sequential([

Dense(128, activation='relu', input_shape=input_shape),

Dense(64, activation='relu'),

Dense(1, activation='sigmoid')

])

model.compile(optimizer='adam', loss='binary_crossentropy', metrics=['accuracy'])

return model</p>

Placeholder for training the AI model

def train_ai_model(model, X_train, y_train, X_val, y_val):

model.fit(X_train, y_train, epochs=10, validation_data=(X_val, y_val))

return model</p>

Placeholder for evaluating the AI model

def evaluate_ai_model(model, X_test, y_test):

predictions = model.predict(X_test)

predictions = (predictions > 0.5).astype(int)

accuracy = accuracy_score(y_test, predictions)

print(f'Model Accuracy: {accuracy:.2f}')</p>

Placeholder for data quality and ethical analysis

def data_quality_and_ethical_analysis(data):

Placeholder for data quality checks (e.g., missing values, data distribution)

Placeholder for ethical analysis (e.g., bias detection, fairness assessment)

pass</p>

Placeholder for regulatory compliance analysis

def regulatory_compliance_analysis():

Placeholder for analyzing compliance with regulatory standards

pass</p>

Placeholder for economic and sustainability analysis

def economic_sustainability_analysis():

Placeholder for cost-benefit analysis and sustainability assessment

pass</p>

Main function to execute the proposed solution

def main():

Load and preprocess data

data = load_and_preprocess_data('drug_discovery_data.csv')

X = data.drop('target', axis=1)

y = data['target']</p>

Split data into training, validation, and test sets

X_train, X_temp, y_train, y_temp = train_test_split(X, y, test_size=0.3, random_state=42)

X_val, X_test, y_val, y_test = train_test_split(X_temp, y_temp, test_size=0.5, random_state=42)

Create and train AI model

model = create_ai_model(input_shape=(X_train.shape[1],))

model = train_ai_model(model, X_train, y_train, X_val, y_val)

Evaluate AI model

evaluate_ai_model(model, X_test, y_test)

Perform data quality and ethical analysis

data_quality_and_ethical_analysis(data)

Perform regulatory compliance analysis

regulatory_compliance_analysis()

Perform economic and sustainability analysis

economic_sustainability_analysis()

if name == 'main':

main()</p>

14-Explanation:

1. The load_and_preprocess_data is simply a placeholder for loading some data and pre-processing (normalization, feature selection such) which we will do in the next steps.

2. Function:- Create AI Model : This function creates a sample Neural network model with TensorFlow/Keras. This one should be replaced with a more intelligent model, e.g., GNN or RL module (if needed).

3. Then train model : This is the function `train_ai_model(), in this function we load the AI model and then train on training and validation.

4. Model Evaluation: After training on the test data set, it will take Model and give a % accuracy of it by displaying a score output derived from predict API.

5. Data Quality and Ethical Analysis - Function data_quality_and_ethical_analysis acts a placeholder to prepare the data quality check and ethical analysis.

6. Compliance analysis (Place holder on the `regulatory_compliance_analysis` function.)

7. Economic and Sustainability Summary Analysis: This is for the cost benefit and sustainability analysis that utilized a function economic_sustainability_analysis.

Its a basic pattern to then augment with other more detailed and advanced implementations of your context specific needs in research and projects.

15-Conclusion

At the root of is the lack of efficacies and high costs due to established drug discovery process and pharma manufacturing frameworks broadly related to historical drugs as well are becoming sheerly transparent when affected by COVID-19 situation. One potential solution is to apply AI in improving different stages of drug discovery and manufacturing, which creates respective challenges about the quality of data, ethics used, and other eventual outcomes.

This research is important because it addresses fundamental limitations and costs in current methods of drug discovery and manufacturing, which have been exacerbated by the COVID-19 pandemic. Utilizing AI and other Ackure methodologies, the research provides potential solutions to improve efficiency, lower costs and have increased success rates for drug development. It also rectifies data quality and ethical issues, as well as helps with regulatory efforts and showcases the transformative power of AI-driven biotech startups. In all, though all this research we are trying to establish the ways that AI is disrupting the pharmaceutical lifecycle and how far we still have to go before it can pave the way for future advancements.

The following research addresses a deep study of conventional drug discovery challenges, unification of different AI methodologies into effective strategies, overcoming data and ethical issues, role of cutting edge computational hardware advancements, FDA compliance (efforts), AI performance during the COVID-19 pandemic, emerging trends in AI based Biotech startups.

The principal idea is based on the extensive use of AI technologies as well as new manufacturing processes to break with tradition inefficencies and high costs in drug development and pharmaceutical production. This is an initiative that responds to the pressing need for innovation that has been underlined by the COVID-19 pandemic, and provides a strategic plan to improve drug development and manufacturing in the mess of challenges around data quality, ethical principles and realization.

References

[1] Borgwardt, K., & Ong, C. S. (2023). AI in drug discovery and its clinical relevance. Retrieved from [URL].] Oprea, T. I., & Tropsha, A. (2023). Artificial Intelligence in Molecular and Clinical Pharmacology. Journal of Pharmacology & Therapeutics, 1(2), 123-135. doi:10.1016/j.jpharmthera.2023.05.001.

[2]]Hughes, J. P., Rees, S. S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British Journal of Pharmacology, 162(6), 1239-1249. doi:10.1111/j.1476-5381.2010.01127.x.

[3]]Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., ... & Overington, J. P. (2017). A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery, 16(1), 19-34. doi:10.1038/nrd.2016.230.

[4]][Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., ... & Zhao, S. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463-477. doi:10.1038/s41573-019-0024-5.

[5]][Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020). Artificial intelligence in COVID-19 drug repurposing. The Lancet Digital Health, 2(12), e667-e676. doi:10.1016/S2589-7500(20)30192-8.

[6]]Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., ... & Kavukcuoglu, K. (2020). Improved protein structure prediction using potentials from deep learning. Nature, 577(7792), 706-710. doi:10.1038/s41586-019-1923-7.

[7]]Schneider, G. (2018). Automating drug discovery. Nature Reviews Drug Discovery, 17(2), 97-113. doi:10.1038/nrd.2017.232.

[8]]Elton, D. C., Boukouvalas, Z., Fuge, M. D., & Chung, P. W. (2019). Deep learning for molecular design—a review of the state of the art. Molecular Systems Design & Engineering, 4(6), 828-849. doi:10.1039/C9ME00039A.

[9]]Goh, G. B., Hodas, N. O., & Vishnu, A. (2017). Deep learning for computational chemistry. Journal of Computational Chemistry, 38(16), 1291-1307. doi:10.1002/jcc.24764.

[10]]The National Academies of Sciences, Engineering, and Medicine. Innovation in Pharmaceutical Manufacturing on the Horizon: Technical Challenge, Regulatory Issues, and Recommendations. 2021. In "Artificial Intelligence in Drug Manufacturing"【18:0†Artificial Intelligence in Drug Manufacturin.pdf】.

[11] Center for Drug Evaluation and Research. Artificial Intelligence in Drug Manufacturing. Discussion Paper. 2023. In "Artificial Intelligence in Drug Manufacturing"【18:2†Artificial Intelligence in Drug Manufacturin.pdf】.

[12] Goel, A., Davies, J. Artificial Intelligence. In Cambridge Handbook of Intelligence; Cambridge University Press: Cambridge, UK, 2011; pp. 468–482【18:4†ddc-03-00009.pdf】.

[13] Chan, H.S., Shan, H., Dahoun, T., Vogel, H., Yuan, S. Advancing drug discovery via artificial intelligence. Trends Pharmacol. Sci. 2019, 40, 592–604【18:5†ddc-03-00009.pdf】.